Therapeutic Antibody Program

Monoclonal Antibody Therapeutics

After many years of development, therapeutic antibody products have demonstrated significant success in the clinic and commercial markets. In addition to the APC technology that uses recombinant antibody technology, Celldex is also developing therapeutic human monoclonal antibody products. Our lead programs are for oncology targets. Celldex has access through a research and commercialization agreement with Medarex to the UltiMAb® Technology for generating fully human monoclonal antibodies. Under this agreement, Celldex can exercise up to ten separate licenses to develop and commercialize therapeutic antibody products. One program under this agreement is currently in preclinical development.

  • The Medarex UltiMAb® technology: this is a new class of vaccines based on our proprietary antibody-targeted vaccine technology that is used to generate an immune response against cancer or other diseases.
  • The Type I Fcα receptror: Celldex is in preclinical development for therapeutic human antibodies to a signaling molecule known as CD89 or Fcα receptor type I (FcαRI). FcαRI is expressed by some white blood cells and leukemic cell lines, and has been shown to be important in controlling inflammation and tumor growth in animal models.

For citations related to human antibody technologies and CD89 targeting click here

Print Page